TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Can-Fite BioPharma ( (CANF) ).
On November 18, 2025, Can-Fite BioPharma Ltd. announced a significant milestone in its treatment of advanced liver cancer with Namodenoson. A patient treated in a Phase II study has achieved a 9-year survival with a complete response, remaining cancer-free. This breakthrough underscores Namodenoson’s potential as a potent anti-cancer agent with excellent tolerability. The company is currently enrolling patients for a pivotal Phase III trial in Europe, Israel, and the U.S., targeting hepatocellular carcinoma as a second or third-line treatment. Namodenoson holds Orphan Drug and Fast Track status with the FDA and EMA, highlighting its promising role in the liver cancer treatment market, which is projected to reach $6.1 billion by 2027.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.
Can-Fite BioPharma’s stock score is primarily impacted by its weak financial performance and bearish technical indicators. The lack of profitability and absence of valuation metrics further contribute to the low score. Strategic improvements are necessary to enhance financial stability and investor confidence.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing small molecule drugs targeting oncological and inflammatory diseases. The company is in the advanced clinical stage and has a platform technology aimed at multi-billion-dollar markets in cancer, liver, and inflammatory disease treatments. Its lead drug candidates include Namodenoson, which is being evaluated for hepatocellular carcinoma, metabolic dysfunction-associated steatohepatitis, and pancreatic cancer, and Piclidenoson for psoriasis. Can-Fite’s drugs have shown an excellent safety profile in clinical studies.
Average Trading Volume: 197,353
Technical Sentiment Signal: Sell
Current Market Cap: $15.75M
Find detailed analytics on CANF stock on TipRanks’ Stock Analysis page.